In conclusion, we identified vortioxetine hydrobromide, a novel dual JAK2/SRC inhibitor, inhibited gastric cancer cell proliferation, through reducing STAT3 dimerization and nuclear translocation in vivo and in vitro. Here, JAK2 is linked to gastric cancer.